Fritextsökning
Innehållstyper
-
A new giant among our microscopes
Two technologies in one machine.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...
-
Trots löfte – RFK Jr. ska se över barnvaccinationer
För att släppas fram till posten som USA:s hälsominister lovade Robert F Kennedy Jr. att inte ändra de nuvarande vaccinationsprogrammen. Men nu är det just det ...
-
Anna Törner: The minute between life and death
“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...
-
The First Multi-Technology System from ZEISS
Microscope and measuring machine in one.
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...
-
Bayer has cut 1,500 roles – so far
German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...
-
Norwegian cancer research companies merge
The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.
-
Accelerate your Research with AI-Powered Image Analysis
Comprehensive eBook from ZEISS.
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
No demand for new Covid vaccine – “It will probably be discarded”
So far, just under 6 000 doses of the Covid vaccine from Novavax have been used in Sweden, leaving over 1.4 million doses in stock. “They will probably be disca...
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...
-
Lundbeck behind the first EU-approved intravenous migraine treatment
A preventive, intravenous treatment for migraines has been approved in the EU for the first time.
-
ZEISS Metrology Expert Tips
New video series provides valuable expert knowledge.
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
This is how Anette Steenberg will put Medicon Valley on the world map
Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to a...
-
InfoTech Scandinavia AB / Advantum
-
BD separerar affärsområdet Biosciences – fokuserar på medtech
BD slimmar portföljen och avyttrar affärsområdena bioscience och diagnostik. “Nya BD” ska bli ett helgjutet medicinteknikföretag.
-
Källor: FDA:s vaccinchef tvingas bort – riktar skarp kritik mot Kennedy
Vaccinchefen vid FDA lämnar sin post och kritiserar samtidigt landets hälsominister för att ha låtit ”desinformation och lögner” styra hans tankar om vacciners säkerhet.
-
Learn from Speakers from Leading MedTech Companies
Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.
-
CSL Behring: Nya terapier kräver nya betalningsmodeller
DEBATT: NT-rådets beslut att inte rekommendera en genterapi för hemofili på grund av kostnad och osäker effektlängd belyser vikten av att terapier mot sällsynta...
-
The new ZEISS Celldiscoverer 7 has been launched
Adaptable automation for advanced workflows.